CAPITOLI DI LIBRI

1) M. Venturini, L. Del Mastro, O. Garrone. Terapie biologiche. In Basi biologiche dei trattamenti antitumorali pp 97-117. Accademia Nazionale di Medicina. Forum per la formazione biomedica, 1994. 2) M. Merlano, C. Granetto, O. Garrone, G. Numico. Role of integrating chemotherapy and radiotherapy in oral cancer. In Contemporary Issues in Oral Cancer. Oxford University Press 2000. 3) M. Merlano, O. Garrone. Tumori del distretto cervico-facciale. In Oncologia medica pratica. Pag. 465-478 Soc. Ed. Universo Roma 2000. 4) M. Merlano, O. Garrone. Tumori del distretto cervico-facciale. In Oncologia medica pratica. Pag. 995-1013. Seconda Edizione Soc. Ed. Universo Roma 2005. 5) M. Merlano, O. Garrone: Tumori del distretto cervico-facciale. In Oncologia medica pratica. Pag. 1507-1528. Terza edizione Soc. Ed. Universo Roma 2010.

Garrone O, Bertelli, G, Principe E, Lewis PD, Occelli M, Miraglio E, Merlano MC.

A prospective, randomised study of transvaginal ultrasound effect of tamoxifen and exemestane in postmenopausal women with early  breast  cancer. Tumori 2014, in press.

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

Role of the reni-angiotensin-aldosterone system and the glutathione S-trnsferase Mu, Pi and Theta gene plymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers 2013 Aug 30 [Epub ahed of print]

Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L.

Phase II open-label study of benacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Breast 2013 Apr 30 [Epub ahed of print]

Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, Marroni P, Bighin C, Mansutti M, Puglisi F, Porpiglia M, Ponzone R, Bisagni G, Garrone O, Cavazzini G, Clavarezza M, Del Mastro L.

Plasma estrone sulfate concentrations and genetica variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res Treat 2013 Jan ;137(1) :167-74

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.

Site-specific methylation in the CCAAT/enhancer binding protein delta (CEBPd) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 Jul 10.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

NT5E CpG Island methylation is a favourable breast cancer biomarker. Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

Methylation of the calcium channel regulatory subunit a2d-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analisys. Cardiovasc Toxicol. 2012;12(2):135-42.

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T.

High frequency of complex TP53 mutations in CNS metastases from breast cancer..Br J Cancer. 2012 Jan 17;106(2):397-404. doi: 10.1038/bjc.2011.464. Epub 2011 Dec 20.

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi, S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M.

Effect of gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011 Jul 20;306(3):269-76

Numico G, Occelli M, Russi EG, Silvestris N, Pasero R, Fea E, Granetto C, Di Costanzo G, Colantonio I, Gasco M, Garrone O, Polla V, Merlano MC.

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parametrs and PaP score. Support Care Cancer 2011 November;19(1):1823-30.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol. 2010 Nov;37(5):1219-28.

Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, Gasco M, Lo Nigro C, Vitiello R, Violante S, Garrone O.  

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol. 2010 Sep 1. [Epub ahead of print]

Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro L.

A multicenter phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first- line therapy in metastatic breast cancer. Breast. 2010 Oct;19(5):333-8. Epub 2010 Feb 24.

Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M, Merlano M.

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 2009 Nov 26. [Epub ahead of print]

Camerini A, Rondini M, Garrone O, Valsuani C, Donati S, Siclari O, Sgambato A, Tartarelli G, Vincenti M, Mattiot VP, Porta RP, Puccetti C, Puccinelli P, Amoroso D.

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1450-5.

Numico G, Anfossi, M, Bertelli, G, Russi E, Cento G, Silvestris N, Granetto C, Di Costanzo G, Occelli M, Fea E, Garrone O, Gasco M, Colantonio I, Merlano M.

The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Ann Oncol 2009 20(5).941-5.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A.

 Identification of CDK 10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008 Feb;13(2):91-104.

Merlano M, Garrone O.

Treatment of advanced head and neck cancer with cetuximab. Int J Biol Markers 2007 Jan-Mar, 22 (suppl 4):S71-76.

P Smith, LJ Nicholson, N Syed, A Payne, L Hiller, O Garrone, M Occelli, M Gasco, T Crook.

Epigenetic inactivation implies independent functions for insuline-like growth factor binding protein (IGFBP)- related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 2007;13(14).

Numico G, Russi EG, Vitello R, Sorrentino C, Colantonio I, Cipolat M, Taglianti RV, Pelissero A, Fea E, Granetto C, Di Costanzo G, Gasco M, Garrone O, Occelli M, Merlano M.

Gemcitabine and cisplatin in a concomitant alternatine chemoradiotherapy program for locally advanced head and neck cancer: a pharmacology-guided schedule. Int J radiat Oncol Biol Phys 2006 Nov 1;66(3):731-7.

Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM.

DRAM a p-53-induced modulator of autophagy is critical for apoptosis. Cell 2006, July 14;126(1);121-34.

Bertelli G., Garrone O., Merlano M., Occelli M., Bertolotti L., Castiglione F., Pepi F., Fusco O., Del Mastro L., Leonard R.C.

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2006 Jan 12;69(6):471-477.

Bertelli G., Heouaine A., Arena G., Botto A., Garrone O., Colantonio I., Occelli M., Fea E., Giubergia S., Merlano M.

Weekly docetaxel and zolendronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 2006 Jan;57(1):46-51.

Garrone O.

 Indicazioni e limiti della terapia ormonale di seconda linea. International trends in Oncolology vol IX n 3/2005 (Supp).

G. Numico, I. Colantonio, M. Gasco, G. Bertelli, O. Garrone, M. Occelli, E. Fea, G. Di Costanzo, C. Granetto, A. Heouaine, E. Russi, M. Merlano.

Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Research 25:2555-2560 (2005).

M. Merlano, E.G. Russi, G: Numico, I. Colantonio, O. Garrone, A. Pelissero, C. Granetto, M. Gasco, G. Di Costanzo, A, Heouaine, R. Vigna Taglianti, M. Cipolat.

Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. Radiother Oncol 75 (2005) 193-196.

Bertelli G., Garrone O., Bertolotti L., Occelli M., Conforti S., Marzano N., Febbraro A, Carlini P., Liossi C., Del Mastro L., Leonard R.C.

Manteinance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 2005;68(4-6):364-70.

Numico G., Garrone O., Dongiovanni V., Silvestris V., Colantonio I., Di Costanzo G., Granetto C., Occelli M., Fea E., Heouaine A., Gasco M., Merlano M.

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005 Mar 1:103(5):994-9.

O. Garrone, E. Principe, M. Occelli, M. Mercuri, G. Numico, C. Granetto, G. Di Costanzo, P.D. Rattazzi, M. Merlano.

A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. Anti-Cancer Drugs 2004, 15:23-27.

M. Venturini, A. Durando, O. Garrone, M.A. Colozza, A. Contu, I. Stevani, F. Genta, C. Bighin, A. Lambiase, L. Del Mastro.

Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 97(5); 1174-1180, 2003.

M. Venturini, L. Del Mastro, O. Garrone, C. Angiolini, M. Merlano, M. Bergaglio, G. Tolino, A. Lambiase, A. Baldini, G. Canavese, R. Rosso. Phase I.

Dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy in advanced breast cancer. Ann Oncol 13(4), 546-552, 2002.

G. Numico, F. Castiglione, C. Granetto, O. Garrone, G. Mariani, G. Di Costanzo, P. La Ciura, M. Gasco, O. Ostellino, G. Porcile, M. Merlano.

Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35 (2002) 59-64.

G. Bertelli, O. Garrone, C. Bighin, D. Dini. Correspondence re: Cicchetti S, Jemec B, Gault DT

Two case reports of vinorelbine extravasation: management and review of the literature.Tumori 86:289-292, 2000.

M. Valenzano, G.F. Bertelli, S. Costantini, A. Corticelli, L. Del Mastro, R. Paoletti, O. Garrone, R. Rissone.

Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in tamoxifen-treated patients. Eur J Gynaec Oncol 2001, 6, 441-444.

G. Morasso, M. Costantini, P. Viterbori, F. Bonci, L. Del Mastro, M. Musso, O. Garrone, M. Venturini.

Predicting mood disorders in bresat cancer patients. Eur J Cancer 37 (2001) 216-223.

O. Garrone.

La malattia metastatica: studi GONO-MIG e stato dell’arte. 4° Congresso Nazionale Gruppo Oncologico di Nord-Ovest. Pag. 87-91, 1999.

M. Esposito, M. Venturini, M.O. Vannozzi, G. Tolino, G. Lunardi, O. Garrone, C. Angiolini, M. Viale, M. Bergaglio, L. Del Mastro, R. Rosso.

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer. J Clin Oncol 17:1132-1140, 1999.

M Costantini, M Musso, P Viterbori, F Bonci, L Del Mastro, O Garrone, M Venturini, G Morasso.

Detecting psychological distress in cancer patients: validity of the italian version of the hospital hospital anxiety and depression scale. Support Care Cancer 7:121-127, 1999.

M Merlano, O Garrone.

Il trattamento del cancro della laringe: il trattamento chemioterapico. Recenti progressi in medicina, vol 89, numero 12 Dicembre 1998.

D Dini, L Del Mastro, A Gozza, R Lionetto, O Garrone, G Forno, G Vidili, G Bertelli, M Venturini.

The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. Ann Oncol 9; 187-190, 1998.

R Rosso, L Del Mastro, M Venturini, M Bergaglio, W Pasquetti, O Garrone.

Uso dell’eritropoietina in oncologia. Tumori 83 (Suppl.): S26-S30, 1997.

G Bertelli, M Venturini, L Del Mastro, O Garrone, M Cosso, C Gustavino, E Cusimano, T Guido, G Nicolò, R Rosso.

Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Br Cancer Res Treat 47: 41-46, 1998.

L Del Mastro, M Venturini, R Lionetto, O Garrone, G Melioli, W Pasquetti, MR Sertoli, G Bertelli, G Canavese, M Costantini, R Rosso.

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15 2715-2721, 1997.  

L Del Mastro, M Venturini, M Costantini, O Garrone, MR Sertoli, G Bertelli, AM Machì, R Rosso.

Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with -thalassemia minor. J Nat Cancer Inst, 89:455-456, 1997.

M Venturini, A Michelotti, L Del Mastro, L Gallo, F Carnino, O Garrone, C Tibaldi, N Molea, RC Bellina, P Pronzato, P Cyrus, J Vinke, F Testore, M Guelfi, R Lionetto, P Bruzzi, PF Conte, R Rosso.

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996.

M Venturini, L Del Mastro, O Garrone, M Bergaglio, R Rosso.

Mobilizzazione di progenitori emopoietici nel sangue periferico con chemioterapia convenzionale. Tumori 82 (Suppl.): S14-SS18, 1996.

M Venturini, L Del Mastro, F Testore, M Danova, O Garrone, C Lanfranco, F Latini, MR Sertoli, R Lionetto, P Queirolo, A Ardizzoni, R Rosso.

Erythropoietin and granulocyte macrophage colony-stimulating factor allow acceleration and dose escalation of CEF chemotherapy. A dose finding study in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology, 1996 38:487-494

M Venturini, P Bruzzi, L Del Mastro, O Garrone, GF Bertelli, M Guelfi, S Pastorino, R Rosso, MR Sertoli.

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first line CEF regimen in patients with metastatic breast cancer. J Clin Oncol, 14:764-773, 1996

L del Mastro, M Venturini, PG Giannessi, A Vigani, O Garrone, F Carnino, P Russo, PG Galletti, R Rosso, PF Conte.

Intraperitoneal infusion of recombinant human Tumor Necrosis Factor and mitoxantrone in neoplastic ascites: a feasibility study. Anticancer Research 15:2207-2212, 1995.

G Bertelli, A Gozza, G Vidili, S Silvestro, M Venturini, L Del Mastro, O Garrone, R Rosso, D Dini.

Topical dimethylsulfoxide for the prevention of soft tissue injiury after extravasation of vescicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13:2851-2855, 1995.

M Venturini, L Del Mastro, G Melioli, E Balleari, O Garrone, W Pasquetti, C Bason, R Ghio, P Bruzzi, R Rosso.

Release of Peripheral Blood Progenitor Cells during standard-dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus G-CSF for breast cancer therapy. Cancer 1994: 74:2300-6.

L Del Mastro, O Garrone, M Guenzi, F Cafiero, G Nicolò, R Rosso, M Venturini.

Angiosarcoma of residual breast after conservative surgery and radiotherapy for primary carcinoma. Annals of Oncology 5: 163-165, 1994.

L Del Mastro, O Garrone, M Venturini, MR Sertoli, G Canavese, A Catturich, M. Guenzi, R. Rosso

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte-colony stimulating factor as adjuvant therapy in early breast cancer. Eur J Cancer Vol 30A No. 5, 606-610; 1994

O Garrone, L Del Mastro, GL Mariani, A Ardizzoni, M Venturini, R Rosso.

Studio di fattibilità del regime ciclofosfamide methotrexate e 5-fluorouracile somministrati per via endovenosa con e senza "granulocyte colony-stimulating factor" nel carcinoma mammario operato. Minerva Medica 1993; 84:467-472.

A Ardizzoni, M Venturini, L Crinò, MR Sertoli, P Bruzzi, MC Pennucci, GL Mariani, O Garrone, S Bracarda, R Rosso, N Van Zandwijk.

High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony-stimulating factor, in the small cell lung cancer. Eur J Cancer 29A, 5, 687-692, 1993.

Venturini M, Addamo GF, Garrone O, Silvestro S, Russo P, Rosso R.

Utilizzo clinico del GM-CSF in oncologia. In XIV Corso di Aggiornamento in Oncologia Medica AIOM. Ed. G. Mustacchi et al., 299-308, 1992.

M Venturini, L Del Mastro, A Ardizzoni, MR Sertoli, GL Mariani, MC Pennucci, O Garrone, S Silvestro, GF Addamo, P Queirolo, R Rosso.

High dose-intensity chemotherapy without bone-marrow support: role of granulocyte-macrophage colony-stimulating factor. Annals of The New York Accademy of Sciences, 698:389-99, 1993.